<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069573</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE-36787714.0.0000.5152</org_study_id>
    <nct_id>NCT03069573</nct_id>
  </id_info>
  <brief_title>Phenotypic Characterization and Biomarkers Investigation for Eosinophilic Esophagitis in Pediatric Patients</brief_title>
  <official_title>Phenotypic Characterization of Pediatric Patients With Esophageal Eosinophilia and Biomarkers Investigation for the Diagnosis of Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Uberlandia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Uberlandia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out some potential biomarkers for the Eosinophilic
      Esophagitis (EoE) in pediatric patients through the prospective clinical characterization and
      assessment of samples collected during the diagnostic process
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study collects clinical information from pediatric patients between 0-18 years old who
      have been undergoing upper gastrointestinal endoscopy due to general complaints. The
      demographic, clinical symptoms, endoscopy, pH monitoring, and histology data are assessed
      during the diagnostic process. In the baseline endoscopy procedure samples (blood, saliva,
      esophageal tissue, and esophageal mucus) are taken. After diagnostic process of EoE and
      Gastroesophageal reflux disease (GERD) supported by International Guidelines the patients are
      divided into three groups - EoE, GERD, and Control.

      The techniques are used for patients characterization and assessment:

        1. Symptoms score: General symptom score and/or Pediatric Eosinophilic Esophagitis Symptom
           Score (PEESS v2.0) - translated and adapted version for Brazilian Portuguese

        2. Endoscopic Score: Eosinophilic Esophagitis (EoE) Endoscopic Reference Score (EREFS)

        3. Peak eosinophil count (PEC) and histological features description

        4. Proteomic analyses

        5. Microbiome analyses

        6. Immunohistochemistry analyses
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Biomarkers for the diagnose of Pediatric Eosinophil Esophagitis</measure>
    <time_frame>2016 August - 2017 March and 2018 November-December</time_frame>
    <description>Assessment of the facility of biomarkers to identify the EoE patients and the inflammatory or fibrosis phenotype by immunohistochemistry analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic features of EoE</measure>
    <time_frame>2017 January-March and 2018 November-December</time_frame>
    <description>Assessment of the facility of endoscopic score for EoE (EREFS) to identify EoE patients and the inflammatory or fibrosis phenotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of active EoE</measure>
    <time_frame>2017 January-March and 2018 November-December</time_frame>
    <description>Assessment of the facility of symptom score for EoE (PEESS v2.0 - Brazilian Portuguese version) to identify active disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological features of EoE</measure>
    <time_frame>2017 January-March and 2018 November-December</time_frame>
    <description>Assessment of the facility of histological features and score to identify the EoE patients and the inflammatory or fibrosis phenotype</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Eosinophilic Esophagitis - EoE</arm_group_label>
    <description>The diagnose of pediatric EoE under current guideline. Samples collection by blood, saliva, esophageal mucus and esophageal tissue are taken for biomarkers investigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastroesophageal reflux disease - GERD</arm_group_label>
    <description>The diagnose of pediatric GERD under current guideline. Samples collection by blood, saliva, esophageal mucus and esophageal tissue are taken for biomarkers investigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>The exclusion diagnose of EoE or GERD. Samples collection by blood, saliva, esophageal mucus and esophageal tissue are taken for biomarkers investigation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, saliva, esophageal tissue, esophageal mucus
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients who are undergoing upper gastrointestinal endoscopy due to general
        complaints in tertiary Public Heathcare Centre
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients who are undergoing upper gastrointestinal endoscopy for diagnostic
             purpose

        Exclusion Criteria:

          -  Pediatric patients who are undergoing upper gastrointestinal endoscopy for therapeutic
             procedures

          -  The presence of other eosinophilic diseases

          -  Patients have been taken corticosteroids and/or gastric acid secretion inhibition
             drugs for the last four weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz Ricardo Goulart, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Uberlandia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina P Barros, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Uberlandia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina P Barros, Professor</last_name>
    <phone>+55 34 32258604</phone>
    <email>cpalmerb@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luiz Ricardo Goulart, Professor</last_name>
    <phone>+55 34 32258440</phone>
    <email>goulartlr@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal University of Uberlandia</name>
      <address>
        <city>Uberl√¢ndia</city>
        <state>Minas Gerais</state>
        <zip>38400-902</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina P Barros, Professor</last_name>
      <phone>+55 34 32258440</phone>
      <email>cpalmerb@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Luiz Ricardo Goulart, Professor</last_name>
      <phone>+55 34 32258604</phone>
      <email>goulartlr@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A, Wershil BK, Rothenberg ME, Aceves SS. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2. doi: 10.1016/j.jaci.2011.02.040. Epub 2011 Apr 7. Review.</citation>
    <PMID>21477849</PMID>
  </reference>
  <reference>
    <citation>Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG, North American Society for Pediatric Gastroenterology Hepatology and Nutrition, European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):498-547. doi: 10.1097/MPG.0b013e3181b7f563.</citation>
    <PMID>19745761</PMID>
  </reference>
  <reference>
    <citation>Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011 Nov 18;11:126. doi: 10.1186/1471-230X-11-126.</citation>
    <PMID>22099448</PMID>
  </reference>
  <reference>
    <citation>Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013 Apr;62(4):489-95. doi: 10.1136/gutjnl-2011-301817. Epub 2012 May 22.</citation>
    <PMID>22619364</PMID>
  </reference>
  <reference>
    <citation>Singla MB, Chehade M, Brizuela D, Maydonovitch CL, Chen YJ, Riffle ME, Achem SR, Moawad FJ. Early Comparison of Inflammatory vs. Fibrostenotic Phenotype in Eosinophilic Esophagitis in a Multicenter Longitudinal Study. Clin Transl Gastroenterol. 2015 Dec 17;6:e132. doi: 10.1038/ctg.2015.62.</citation>
    <PMID>26680264</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Uberlandia</investigator_affiliation>
    <investigator_full_name>Cristina Palmer Barros</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Eosinophilic Esophagitis</keyword>
  <keyword>Gastroesophageal Reflux</keyword>
  <keyword>Diagnose</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The phenotypic characterization by demographic,symptom, endoscopy, histology data description and the presence of potential biomarkers will be published and shared in this platform</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

